The Filing Desk

InfuSystem

INFU · NYSE · Health Care · Financials, fiscal 2016 to 2025

INFU · Last close · November 19, 2026
$14.06
Value InfuSystem yourself

InfuSystem's revenue rose 6.4% to $143 million in fiscal 2025. Its operating margin was 8.3%, up from 5.1% a year earlier. Free cash flow was $24 million, up 23.1%. It paid out $10 million in dividends and buybacks, 41% of free cash flow. The diluted share count fell 2.8%.

INFUSYSTEM HOLDINGS, INC Latest fiscal year ended December 31, 2025 10-K filed February 27, 2026 · 0001628280-26-012804 Updated
Revenue
$143M
6.4%
Operating margin
8.3%
3.2 pts
Net income
$7M
182.6%
Free cash flow
$24M
23.1%
Return on capital
9.6%
5.4 pts
Market cap
$297M
Nov 19 close
P/E
32.0x
On $0.44 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What InfuSystem does

InfuSystem provides equipment and services that let patients continue treatments at home after leaving a clinic. Its customers are makers of durable medical equipment and health care providers such as hospitals, oncology practices and ambulatory surgery centers. It is based in Rochester Hills, Michigan, and works from seven locations in the United States and Canada.

It has two platforms. Patient Services is its main one. It supplies the equipment and treatment supplies, handles orders and delivery, provides nursing support around the clock, bills insurers and keeps the equipment inspected and repaired. Its experience is mainly in oncology, and it says it wants to extend the model to other types of equipment. Device Solutions covers equipment rentals and sales, supply sales and equipment support services for providers.

Much of its revenue comes from insurers and other third-party payers that pay for the care, so it relies on estimates of what it will collect from them.

Its biggest risks, as it describes them

  • Changes to the health care reimbursement system could hurt its business.
  • It depends on estimates of how much it will collect from insurers and other payers.
  • Losing a relationship with one or more payers, or having too much revenue from a few payers.
  • New studies could show that treatments that don't use its pumps work as well as ones that do.
From InfuSystem's annual report on Form 10-K, filed February 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2019 to 2025, earnings per share grew 28.1% a year and net income 29.5% a year, as new shares raised the share count by 1% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments00003
Debt incl. finance leases3333292420
Net debt (negative means net cash)3333292316
Net debt to EBITDA1.9x2.2x1.7x1.2x0.7x
Debt to equity0.7x0.7x0.6x0.4x0.3x
Interest coverage2.0x1.2x1.9x3.9x9.2x
Current ratio1.7x1.7x1.9x1.8x1.8x
Quick ratio1.4x1.4x1.5x1.4x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project InfuSystem's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What InfuSystem says to expect

  • Full year 2026: net revenue and adjusted EBITDA marginInfuSystem is reaffirming annual net revenue guidance for the full year 2026. After adjusting for the impact of the reduced revenue related to the GE Healthcare contract restructuring, pro-forma net revenue growth is estimated to be between 6% and 8% for 2026. We also are continuing to forecast Adjusted EBITDA margin (non-GAAP) to be in the low-to-mid 20% range.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $150,396 of InfuSystem shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
May 11, 2026Carrie LachancePresident and CEO, DirectorBought1,000$8.46$8,460Form 4
May 8, 2026Barry G SteeleExecutive VP and CFOBought7,000$8.71$60,970Form 4
May 8, 2026Paul Andrew GendronDirectorBought5,000$8.88$44,400Form 4
May 8, 2026Carrie LachancePresident and CEO, DirectorBought2,000$8.83$17,660Form 4
Mar 2, 2026Barry G SteeleExecutive VP and CFOBought2,064$9.16$18,906Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score7 of 97 of 98 of 9
Rule of 4022.6%21.6%23.0%
Altman Z''0.450.871.27
Accruals ratio−10.2%−17.5%−17.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassPass
Current ratio rosePassFailFail
Share count didn't riseFailFailPass
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score7 of 97 of 98 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put InfuSystem side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
InfuSystemFY256.4%8.3%16.6%9.6%0.7x8
NeuroneticsFY2599.2%−21.1%−14.2%−37.5%—4Compare
Xtant MedicalFY2514.2%5.4%7.6%10.0%−0.5x8Compare
Outset MedicalFY255.1%−55.8%−39.4%−88.0%—6Compare
OraSure TechnologiesFY25−38.1%−62.6%−46.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue7071678197102110126135143
Revenue growth−0.1%0.8%−5.5%20.8%20.1%5.1%7.4%14.4%7.2%6.4%
Gross profit45434047595861637080
Research and development——————————
Operating income1−4049324712
Net income−0−21−111710127
Diluted EPS (US$)−0.01−0.91−0.050.070.800.060.000.040.110.31
Diluted shares (millions)23232121222222222221
Cash flow
Cash from operations881114201818112024
Capital expenditure0003111111
Free cash flow881111191717101924
Dividends paid0000000000
Share buybacks001000160110
Acquisitions0000080001
Stock-based compensation0111364444
Balance sheet at fiscal year end
Cash and short-term investments34431000003
Debt incl. finance leases32283438393333292420
Total assets96696479979899103104101
Total liabilities46384457564951514643
Shareholders' equity51312022414848525857
Margins and ratios
Gross margin63.5%61.0%58.9%57.8%60.3%57.2%55.1%50.2%52.2%56.0%
Operating margin1.4%−5.4%0.6%4.3%9.1%2.8%1.5%3.2%5.1%8.3%
Net margin−0.3%−29.1%−1.6%1.7%17.8%1.4%0.0%0.7%1.7%4.6%
Free cash flow margin11.0%10.7%16.6%13.5%19.7%16.9%15.0%8.1%14.4%16.6%
Rule of 40 (growth + FCF margin)10.9%11.5%11.0%34.3%39.8%22.1%22.4%22.6%21.6%23.0%
Return on capital0.9%−4.5%0.6%5.8%13.8%3.7%1.0%2.5%4.2%9.6%
Return on equity−0.4%−50.7%−4.3%6.4%55.0%3.2%0.0%1.7%4.3%11.5%
Return on assets−0.2%−25.1%−1.6%1.9%19.7%1.5%0.0%0.9%2.3%6.5%
Net debt to EBITDA2.4x2.9x2.5x2.2x1.3x1.9x2.2x1.7x1.2x0.7x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: InfuSystem's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with InfuSystem.